Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery

被引:0
|
作者
Y Wang
Z Yang
S Liu
T Kon
A Krol
C-Y Li
F Yuan
机构
[1] Duke University,Department of Biomedical Engineering
[2] Duke University Medical Center,Department of Radiation Oncology
来源
British Journal of Cancer | 2005年 / 92卷
关键词
gene delivery; virus dissemination; intratumoral infusion;
D O I
暂无
中图分类号
学科分类号
摘要
Systemic virus dissemination is a potential problem during local gene delivery in solid tumours. However, the kinetics and pathways of the dissemination have not been well characterised during the first 24 h after the infusion is started. To this end, we infused adenoviral vectors for luciferase or enhanced green fluorescence protein into three different tumour models in mice. During and/or after the infusion, we determined the amount of adenoviruses in the tumour, blood, and liver, and examined the transgene expression in the liver, lung, blood, and tumour. In addition, we intravenously injected tumour cells expressing luciferase and examined the biodistribution of these cells in the body. We observed transgene expression in the liver and tumour at 24 h after the infusion, but could not detect transgene expression in the blood and lung. The peak concentration of viral vectors in the plasma occurred during the intratumoral infusion. At 10 min after the infusion, few viral vectors remained in the blood and the ratio of copy numbers of adenoviruses between liver and tumour was >2 in 80% and ⩾10 in 40% of the mice. Most tumour cells injected intravenously accumulated in the lung within the first 24 h. Taken together, these data indicated that systemic virus dissemination occurred mainly during the first 10 min after the intratumoral infusion was started, and that the dissemination was due to infusion-induced convective transport of viral vectors into leaky tumour microvessels.
引用
收藏
页码:1414 / 1420
页数:6
相关论文
共 50 条
  • [1] Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery
    Wang, Y
    Yang, Z
    Liu, S
    Kon, T
    Krol, A
    Li, CY
    Yuan, F
    BRITISH JOURNAL OF CANCER, 2005, 92 (08) : 1414 - 1420
  • [2] Nonreplicating Adenoviral Vectors: Improving Tropism and Delivery of Cancer Gene Therapy
    Tessarollo, Nayara Gusmao
    Domingues, Ana Carolina M.
    Antunes, Fernanda
    dos Santos da Luz, Jean Carlos
    Rodrigues, Otavio Augusto
    Dutra Cerqueira, Otto Luiz
    Strauss, Bryan E.
    CANCERS, 2021, 13 (08)
  • [3] Membrane coating for nonreplicating adenoviral vectors aids gene delivery in a murine model of melanoma
    Tessarollo, N. G.
    Domingues, A. C. M.
    Strauss, B. E.
    HUMAN GENE THERAPY, 2021, 32 (19-20) : A34 - A35
  • [4] Adenoviral vectors: Systemic delivery and tumor targeting
    Green, NK
    Seymour, LW
    CANCER GENE THERAPY, 2002, 9 (12) : 1036 - 1042
  • [5] Adenoviral vectors: Systemic delivery and tumor targeting
    Nicola K Green
    Leonard W Seymour
    Cancer Gene Therapy, 2002, 9 : 1036 - 1042
  • [6] In vivo gene transfer to pancreatic beta cells by systemic delivery of adenoviral vectors
    Ayuso, E
    Chillón, M
    Agudo, J
    Haurigot, V
    Bosch, A
    Carretero, A
    Otaegui, PJ
    Bosch, F
    HUMAN GENE THERAPY, 2004, 15 (08) : 805 - 812
  • [7] Delivery of adenoviral vectors to the prostate for gene therapy
    Lu, Y
    Carraher, J
    Zhang, Y
    Armstrong, J
    Lerner, J
    Rogers, WP
    Steiner, MS
    CANCER GENE THERAPY, 1999, 6 (01) : 64 - 72
  • [8] Delivery of adenoviral vectors to the prostate for gene therapy
    Yi Lu
    John Carraher
    Yu Zhang
    Jianling Armstrong
    Jody Lerner
    William P Rogers
    Mitchell S Steiner
    Cancer Gene Therapy, 1999, 6 : 64 - 72
  • [9] Adenoviral vectors for improved gene delivery to the inner ear
    Praetorius, Mark
    Brough, Douglas E.
    Hsu, Chi
    Plinkert, Peter K.
    Pfannenstiel, Susanna C.
    Staecker, Hinrich
    HEARING RESEARCH, 2009, 248 (1-2) : 31 - 38
  • [10] Targeted gene delivery by modified recombinant adenoviral vectors
    Curiel, DT
    CANCER GENE THERAPY, 1997, 4 (05) : 321 - 321